Health Condition 1: null- Parthenium dermatitis patients with Vitamin D deficiency
Conditions
Interventions
Intervention1: Vitamin D: Tablet Vitamin D 60,000 IU / week for 2 months in addition to Standard background therapy (Tab. Azathioprine)
Control Intervention1: Placebo: Similar looking placebo tablet
Sponsors
JIPMER Intramural fund
Eligibility
Inclusion criteria
Inclusion criteria: Clinically diagnosed Parthenium dermatitis patients to be started on systemic treatment with azathioprine Vitamin D deficiency (10-20 ng/ml)
Exclusion criteria
Exclusion criteria: Pregnant and lactating women Individuals already on vitamin D supplementation Liver dysfunction (AST, ALT > 1.5 times the upper limit of normal) Renal dysfunction (Serum creatinine, blood urea > 1.5 times the upper limit of normal) Patients who had participated in other trials within last 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL-10 levels, disease severity scoring (EASI-Erythema Area Severity Index)Timepoint: IL-10 - At baseline and after 2 months Disease severity - At baseline, At the end of 1st month, 2nd month and 3rd month | — |
Secondary
| Measure | Time frame |
|---|---|
| Adherence to medicationTimepoint: At the end of each month till six months;Frequency of relapsesTimepoint: At the end of each month till six months;Need for rescue medicationsTimepoint: At the end of each month till six months;Quality of life indexTimepoint: At baseline, At the end of 1st month, 2nd month and 3rd month | — |
Countries
India
Contacts
Public ContactLaxmisha C
JIPMER
Outcome results
None listed